类化合物的未被发现的神经保护潜力:与神经退行性疾病作斗争的多目标战略
Kalyani Chande1, Rupali Nirmal2, Nutan Varpe2
1Dr. DY Patil College of Pharmacy Akurdi, Pune, Maharashtra 411044 India.
3 Biotech
|November 7, 2025
概括
类化合物在治疗神经退行性疾病 (ND) 中表现有前途,通过保护神经元和减少炎症. 需要进一步的研究来开发这些天然化合物成为有效的低毒性疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 神经退行 (ND) 涉及渐进的神经元损失,导致诸如阿尔茨海默氏症和帕金森氏症等疾病.
- 目前的治疗方法只能提供症状缓解,具有显著的副作用,并且不能阻止疾病的进展.
- 对神经退行性疾病的新,少毒的治疗策略有着迫切的需要.
研究的目的:
- 审查类化合物在治疗神经退行性疾病中的治疗潜力.
- 突出需要进一步研究基于类化合物的疗法.
- 探索类素可能提供神经保护的机制.
主要方法:
- 对化物和神经退行症现有研究的文献综述.
- 对研究类化合物的生物活性,包括抗氧化和神经保护作用的研究进行分析.
- 检查化物如何与与神经元存活和恒温相关的信号通路相互作用.
主要成果:
- 类化合物具有多种生物活性,包括抗氧化和神经保护性质.
- 这些天然化合物可以调节关键信号通路和与ND有关的神经炎症反应.
- 类化合物与转录因子,受体和对神经元健康至关重要的酶等关键分子标相互作用.
结论:
- 类化合物代表了一类有前途的天然化合物,可用于开发新的神经退行性疾病治疗方法.
- 进一步的研究是必要的,以确定特定的神经保护性类化合物,并阐明它们的确切作用机制.
- 需要进行临床研究来评估基于类化合物治疗神经退行性疾病的疗法的疗效和安全性.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
08:23Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
Published on: August 9, 2014
11.8K
相关概念视频
01:22Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
527
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
527
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K